Pneumococcal Meningitis in Adults After Introduction of PCV7 and PCV13, Israel, July 2009-June 2015

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2018 Jun 19

PMID 29912694

Citations 10

Authors

Gili Regev-Yochay

Klaris Reisenberg

Michal Katzir

Yonit Wiener-Well

Galia Rahav

Jacob Strahilevitz

Valery Istomin

Evgenia Tsyba

Avi Peretz

Shirley Khakshoor

Ron Dagan

Affiliations

Soon will be listed here.

Abstract

The indirect effect of pneumococcal conjugate vaccine on adult pneumococcal meningitis has not been thoroughly investigated. We present data from active surveillance on pneumococcal meningitis in adults in Israel occurring during July 2009-June 2015. Pneumococcal meningitis was diagnosed for 221 patients, 9.4% of all invasive pneumococcal disease (IPD) cases. Although overall IPD incidence decreased during the study period, meningitis increased nonsignificantly from 0.66 to 0.85 cases/100,000 population. Incidence of vaccine type (VT) pneumococcal meningitis (VT13) decreased by 70%, but non-VT13 pneumococcal meningitis increased from 0.32 to 0.75 cases/100,000 population (incident rate ratio 2.35, 95% CI 1.27-4.35). Pneumococcal meningitis patients were younger and healthier than nonmeningitis IPD patients, and 20.2% had a history of previous head surgery or cerebrospinal fluid leak compared with <2.0% of nonmeningitis patients (p<0.0001). Non-VT13 types that rarely cause IPD (15B/C, 6C, 23A, 23B, 24F) seem to be emerging as common causes of meningitis.

Citing Articles

Nasopharyngeal carriage of among children aged 30 days to <60 months in Beijing and Shenzhen, China (2018-2021) during pneumococcal conjugate vaccine introduction and the coronavirus disease (COVID-19) pandemic.

Du Q, Liu Z, Wang H, Wang Y, Liu L, Wen X Front Pediatr. 2024; 12:1382165.

PMID: 39318618 PMC: 11421034. DOI: 10.3389/fped.2024.1382165.

How common is otogenic meningitis? A retrospective study in southern Sweden over 18 years.

Bjar N, Hermansson A, Gisselsson-Solen M Infection. 2024; 52(4):1377-1384.

PMID: 38416397 PMC: 11289216. DOI: 10.1007/s15010-024-02195-z.

Characteristics of endovascular pneumococcal infections; a decade of nationwide surveillance study.

Kenig A, Oster Y, Cohen-Poradosu R, Reisenberg K, Wieder-Finesod A, Hershman-Sarafov M Eur J Clin Microbiol Infect Dis. 2022; 41(11):1365-1370.

PMID: 36175812 DOI: 10.1007/s10096-022-04500-w.

Pneumococcal meningitis in adults in 2014-2018 after introduction of pediatric 13-valent pneumococcal conjugate vaccine in Japan.

Chang B, Tamura K, Fujikura H, Watanabe H, Tanabe Y, Kuronuma K Sci Rep. 2022; 12(1):3066.

PMID: 35197497 PMC: 8866494. DOI: 10.1038/s41598-022-06950-w.

Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis.

Chen H, Matsumoto H, Horita N, Hara Y, Kobayashi N, Kaneko T Sci Rep. 2021; 11(1):11865.

PMID: 34088948 PMC: 8178309. DOI: 10.1038/s41598-021-91234-y.

References

van de Beek D, Cabellos C, Dzupova O, Esposito S, Klein M, Kloek A . ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016; 22 Suppl 3:S37-62. DOI: 10.1016/j.cmi.2016.01.007. View

Weinberger D, Trzcinski K, Lu Y, Bogaert D, Brandes A, Galagan J . Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog. 2009; 5(6):e1000476. PMC: 2689349. DOI: 10.1371/journal.ppat.1000476. View

Harboe Z, Dalby T, Weinberger D, Benfield T, Molbak K, Slotved H . Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014; 59(8):1066-73. DOI: 10.1093/cid/ciu524. View

Waight P, Andrews N, Ladhani S, Sheppard C, Slack M, Miller E . Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015; 15(5):535-43. DOI: 10.1016/S1473-3099(15)70044-7. View

Bijlsma M, Brouwer M, Kasanmoentalib E, Kloek A, Lucas M, Tanck M . Community-acquired bacterial meningitis in adults in the Netherlands, 2006-14: a prospective cohort study. Lancet Infect Dis. 2015; 16(3):339-47. DOI: 10.1016/S1473-3099(15)00430-2. View

Castelblanco R, Lee M, Hasbun R . Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study. Lancet Infect Dis. 2014; 14(9):813-9. DOI: 10.1016/S1473-3099(14)70805-9. View

Moore M, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett N . Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015; 15(3):301-9. PMC: 4876855. DOI: 10.1016/S1473-3099(14)71081-3. View

Greenberg D, Givon-Lavi N, Ben-Shimol S, Ziv J, Dagan R . Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years. Vaccine. 2015; 33(36):4623-9. DOI: 10.1016/j.vaccine.2015.06.062. View

Chowers M, Regev-Yochay G, Mor O, Cohen-Poradosu R, Riesenberg K, Zimhony O . Invasive pneumococcal disease (IPD) in HIV infected patients in Israel since the introduction of pneumococcal conjugated vaccines (PCV): Analysis of a nationwide surveillance study, 2009-2014. Hum Vaccin Immunother. 2016; 13(1):216-219. PMC: 5287326. DOI: 10.1080/21645515.2016.1229720. View

10.

Schuchat A, Robinson K, Wenger J, Harrison L, Farley M, Reingold A . Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med. 1998; 337(14):970-6. DOI: 10.1056/NEJM199710023371404. View

11.

Ben-Shimol S, Greenberg D, Givon-Lavi N, Elias N, Glikman D, Rubinstein U . Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. Vaccine. 2012; 30(46):6600-7. DOI: 10.1016/j.vaccine.2012.08.012. View

12.

Alari A, Chaussade H, Domenech de Celles M, Le Fouler L, Varon E, Opatowski L . Impact of pneumococcal conjugate vaccines on pneumococcal meningitis cases in France between 2001 and 2014: a time series analysis. BMC Med. 2016; 14(1):211. PMC: 5175381. DOI: 10.1186/s12916-016-0755-7. View

13.

Tunkel A, Hartman B, Kaplan S, Kaufman B, Roos K, Scheld W . Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004; 39(9):1267-84. DOI: 10.1086/425368. View

14.

Pilishvili T, Lexau C, Farley M, Hadler J, Harrison L, Bennett N . Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2009; 201(1):32-41. DOI: 10.1086/648593. View

15.

de Gans J, van de Beek D . Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002; 347(20):1549-56. DOI: 10.1056/NEJMoa021334. View

16.

Barrett C, Ben-Shimol S, Greenberg D . Differences Between Radiologically Confirmed Pneumonia With and Without Pleural Fluid in Hospitalized Children Younger Than 5 Years in Southern Israel. Clin Pediatr (Phila). 2015; 55(10):897-903. DOI: 10.1177/0009922815616246. View

17.

Thigpen M, Whitney C, Messonnier N, Zell E, Lynfield R, Hadler J . Bacterial meningitis in the United States, 1998-2007. N Engl J Med. 2011; 364(21):2016-25. DOI: 10.1056/NEJMoa1005384. View

18.

Htar M, Madhava H, Balmer P, Christopoulou D, Menegas D, Bonnet E . A review of the impact of pneumococcal polysaccharide conjugate vaccine (7-valent) on pneumococcal meningitis. Adv Ther. 2013; 30(8):748-62. PMC: 3778885. DOI: 10.1007/s12325-013-0051-2. View

19.

Hsu H, Shutt K, Moore M, Beall B, Bennett N, Craig A . Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009; 360(3):244-56. PMC: 4663990. DOI: 10.1056/NEJMoa0800836. View

20.

Kendall B, Dascomb K, Mehta R, Stockmann C, Mason E, Ampofo K . Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children. Vaccine. 2015; 34(4):474-478. DOI: 10.1016/j.vaccine.2015.12.010. View